The FDA has approved Bracco’s gadopiclenol-based contrast agent, Vueway, for IV MRI imaging in neonates and infants.
Vueway is a macrocyclic gadolinium-based contrast agent that delivers effective image enhancement at half the gadolinium dose used in other approved macrocyclic agents, according to a Feb. 23 news release. The approval follows pediatric data from a non-randomized clinical trial and marks an extension from the product’s original 2022 FDA approval for adults and children ages 2 and older.
The expanded label provides clinicians with a low-dose contrast option for the youngest patients, a population especially vulnerable to cumulative exposure. Pediatric radiology leaders said the approval supports safer diagnostic imaging without compromising quality.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.